Loss of c-REL but not NF-κB2 prevents autoimmune disease driven by FasL mutation

Cell Death and Differentiation

Volumn 22, Issue 5, 2015, Pages 767-778

  O'Reilly, L A ^a,b   Hughes, P ^a,c   Lin, A ^a   Waring, P ^b   Siebenlist, U ^d   Jain, R ^a,b   Gray, D H D ^a,b   Gerondakis, S ^e   Strasser, A ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; FAS PROTEIN, MOUSE; FASL PROTEIN, MOUSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NFKB2 PROTEIN, MOUSE; TRANSCRIPTION FACTOR REL;

ANIMAL; AUTOIMMUNE DISEASES; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOUSE; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD95; AUTOIMMUNE DISEASES; FAS LIGAND PROTEIN; MICE; MICE, KNOCKOUT; MUTATION; NF-KAPPA B P52 SUBUNIT; PROTO-ONCOGENE PROTEINS C-REL; SIGNAL TRANSDUCTION;

EID: 84940005913     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.168     Document Type: Article

References (55)

1. Strasser A, Harris AW, Cory S. Bcl-2 transgene inhibits T cell death and perturbs thymic selfcensorship. Cell 1991; 67: 889-899.
2. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005; 435: 590-597.
3. Bouillet P, Purton JF, Godfrey DI, Zhang L-C, Coultas L, Puthalakath H et al. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 2002; 415: 922-926.
4. Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009; 30: 180-192.
5. Hughes PD, Belz GT, Fortner K, Budd RC, Strasser A, Bouillet P. Apoptosis regulators Fas and Bim cooperate in shutdown of chronic immune responses and prevention of autoimmunity. Immunity 2008; 28: 197-205.
6. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314-317.
7. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middelton LA, Lin AY et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995; 81: 935-946.
8. O'Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009; 461: 659-663.
9. Krammer PH. CD95's deadly mission in the immune system. Nature 2000; 407: 789-795.
10. Ahn JH, Park SM, Cho HS, Lee MS, Yoon JB, Vilcek J et al. Non-apoptotic signaling pathways activated by soluble Fas ligand in serum-starved human fibroblasts. Mitogenactivated protein kinases and NF-kappaB-dependent gene expression. J Biol Chem 2001; 276: 47100-47106.
11. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol 2002; 3: 221-227.
12. Gerondakis S, Grumont R, Gugasyan R, Wong L, Isomura I, Ho W et al. Unravelling the complexities of the NF-kappaB signalling pathway using mouse knockout and transgenic models. Oncogene 2006; 25: 6781-6799.
13. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008; 132: 344-362.
14. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006; 25: 6680-6684.
15. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27: 693-733.
16. Brown KD, Claudio E, Siebenlist U. The roles of the classical and alternative nuclear factorkappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther 2008; 10: 212.
17. Pai S, Thomas R. Immune deficiency or hyperactivity-Nf-kappab illuminates autoimmunity. J Autoimmun 2008; 31: 245-251.
18. Zhang B, Wang Z, Ding J, Peterson P, Gunning WT, Ding HF. NF-kappaB2 is required for the control of autoimmunity by regulating the development of medullary thymic epithelial cells. J Biol Chem 2006; 281: 38617-38624.
19. Siebenlist U, Brown K, Claudio E. Control of lymphocyte development by nuclear factor-kappaB. Nat Rev Immunol 2005; 5: 435-445.
20. Flammer JR, Rogatsky I. Minireview: Glucocorticoids in autoimmunity: unexpected targets and mechanisms. Mol Endocrinol 2011; 25: 1075-1086.
21. Grumont RJ, Gerondakis S. The murine c-rel proto-oncogene encodes two mRNAs the expression of which is modulated by lymphoid stimuli. Oncogene Res 1990; 5: 245-254.
22. Gerondakis S, Strasser A, Metcalf D, Grigoriadis G, Scheerlinck J-PY, Grumont RJ. Rel-deficient T cells exhibit defects in production of interleukin 3 and granulocytemacrophage colony-stimulating factor. Proc Natl Acad Sci USA 1996; 93: 3405-3409.
23. Gilmore TD, Gerondakis S. The c-Rel transcription factor in development and disease. Genes Cancer 2011; 2: 695-711.
24. Caamaño JH, Rizzo CA, Durham SK, Barton DS, Raventós-Suárez C, Snapper CM et al. Nuclear factor (NF)-κB2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J Exp Med 998; 87: 85-96.
25. Franzoso G, Carlson L, Poljak L, Shores EW, Epstein S, Leonardi A et al. Mice deficient in nuclear factor (NF)-κB/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med 998; 87: 47-59.
26. Zhu M, Chin RK, Christiansen PA, Lo JC, Liu X, Ware C et al. NF-kappaB2 is required for the establishment of central tolerance through an Aire-dependent pathway. J Clin Invest 2006; 116: 2964-2971.
27. Braun D, Geraldes P, Demengeot J. Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 2003; 20: 15-25.
28. Köntgen F, Grumont RJ, Strasser A, Metcalf D, Li R, Tarlinton D et al. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev 1995; 9: 1965-1977.
29. Werfel T. The role of leukocytes, keratinocytes, and allergen-specific IgE in the development of atopic dermatitis. J Invest Dermatol 2009; 129: 1878-1891.
30. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010; 11: 7-13.
31. Akdis M, Blaser K, Akdis CA. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol 2005; 116: 961-968 quiz 969.
32. Fyhrquist N, Lehtimaki S, Lahl K, Savinko T, Lappetelainen AM, Sparwasser T et al. Foxp3+ cells control Th2 responses in a murine model of atopic dermatitis. J Invest Dermatol 2012; 132: 1672-1680.
33. Isomura I, Palmer S, Grumont RJ, Bunting K, Hoyne G, Wilkinson N et al. c-Rel is required for the development of thymic Foxp3+ CD4 regulatory T cells. J Exp Med 2009; 206: 3001-3014.
34. Mathis D, Benoist C. Aire. Annu Rev Immunol 2009; 27: 287-312.
35. Gray DH, Gavanescu I, Benoist C, Mathis D. Danger-free autoimmune disease in Aire-deficient mice. Proc Natl Acad Sci USA 2007; 104: 18193-18198.
36. Irla M, Hollander G, Reith W. Control of central self-tolerance induction by autoreactive CD4 (+) thymocytes. Trends Immunol 2010; 31: 71-79.
37. Strnad J, Burke JR. IkappaB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challenges. Trends Pharmacol Sci 2007; 28: 142-148.
38. Vallabhapurapu S, Ryseck RP, Malewicz M, Weih DS, Weih F. Inhibition of NF-κB in T cells blocks lymphoproliferation and partially rescues autoimmune disease in gld/gld mice. Eur J Immunol 2001; 31: 2612-2622.
39. Hao Z, Duncan GS, Seagal J, Su YW, Hong C, Haight J et al. Fas receptor expression in germinal-center B cells is essential for Tand B lymphocyte homeostasis. Immunity 2008; 29: 615-627.
40. Basak S, Kim H, Kearns JD, Tergaonkar V, O'Dea E, Werner SL et al. A fourth IkappaB protein within the NF-kappaB signaling module. Cell 2007; 128: 369-381.
41. Ishimaru N, Kishimoto H, Hayashi Y, Sprent J. Regulation of naive T cell function by the NF-kappaB2 pathway. Nat Immunol 2006; 7: 763-772.
42. Brady K, Fitzgerald S, Moynagh PN. Tumour-necrosis-factor-receptor-associated factor 6, NF-kappaB-inducing kinase and IkappaB kinases mediate IgE isotype switching in response to CD40. Biochem J 2000; 350: 735-740.
43. Nakamura H, Aoki M, Tamai K, Oishi M, Ogihara T, Kaneda Y et al. Prevention and regression of atopic dermatitis by ointment containing NF-kB decoy oligodeoxynucleotides in NC/Nga atopic mouse model. Gene Ther 2002; 9: 1221-1229.
44. Zelazowski P, Shen Y, Snapper CM. NF-kappaB/p50 and NF-kappaB/c-Rel differentially regulate the activity of the 3'alphaE-hsl,2 enhancer in normal murine B cells in an activationdependent manner. Int Immunol 2000; 12: 1167-1172.
45. Carrasco D, Cheng J, Lewin A, Warr G, Yang H, Rizzo C et al. Multiple hemopoietic defects and lymphoid hyperplasia in mice lacking the transcriptional activation domain of the c-Rel protein. J Exp Med 1998; 187: 973-984.
46. Campbell IK, Gerondakis S, O'Donnell K, Wicks IP. Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J Clin Invest 2000; 105: 1799-1806.
47. Lamhamedi-Cherradi SE, Zheng S, Hilliard BA, Xu L, Sun J, Alsheadat S et al. Transcriptional regulation of type I diabetes by NF-kappa B. J Immunol 2003; 171: 4886-4892.
48. Chen G, Hardy K, Pagler E, Ma L, Lee S, Gerondakis S et al. The NF-kappaB transcription factor c-Rel is required for Th17 effector cell development in experimental autoimmune encephalomyelitis. J Immunol 2011; 187: 4483-4491.
49. Hilliard BA, Mason N, Xu L, Sun J, Lamhamedi-Cherradi SE, Liou HC et al. Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation. J Clin Invest 2002; 110: 843-850.
50. Chang M, Jin W, Chang JH, Xiao Y, Brittain GC, Yu J et al. The ubiquitin ligase Peli1 negatively regulates T cell activation and prevents autoimmunity. Nat Immunol 2011; 12: 1002-1009.
51. Goodnow CC. Multistep pathogenesis of autoimmune disease. Cell 2007; 130: 25-35.
52. Gray DH, Chidgey AP, Boyd RL. Analysis of thymic stromal cell populations using flow cytometry. J Immunol Methods 2002; 260: 15-28.
53. Gray DH, Fletcher AL, Hammett M, Seach N, Ueno T, Young LF et al. Unbiased analysis, enrichment and purification of thymic stromal cells. J Immunol Methods 2008; 329: 56-66.
54. Seach N, Wong K, Hammett M, Boyd RL, Chidgey AP. Purified enzymes improve isolation and characterization of the adult thymic epithelium. J Immunol Methods 2012; 385: 23-34.
55. Naik S, Vremec D, Wu L, O'Keeffe M, Shortman K. CD8alpha+ mouse spleen dendritic cells do not originate from the CD8alpha- dendritic cell subset. Blood 2003; 102: 601-604.